Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 8/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240151 | 0.87 | SMN1; SMN2 (0.45) | LMNAMAPT | |
| SCHEMBL3240534 | 0.83 | PDK1 (0.37) | CHRNB2CHRNA4PDK1MAPT | |
| SCHEMBL3243776 | 0.82 | RPS6KA3 (0.36) | CSF1R | |
| SCHEMBL3242161 | 0.79 | MET (0.43) | PDK1 | |
| SCHEMBL3240454 | 0.78 | MELK (0.35) | RIPK1 | |
| SCHEMBL3243674 | 0.75 | MAP2K7 (0.40) | LMNAMAPT | |
| SCHEMBL3241929 | 0.74 | ACHE (0.43) | CHRNB2CHRNA4LMNAALDH1A1PDK1 | |
| SCHEMBL3245775 | 0.74 | SMN1; SMN2 (0.40) | LMNAPDK1 | |
| SCHEMBL3236473 | 0.73 | PDK1 (0.37) | CHRNB2CHRNA4PDK1 | |
| SCHEMBL3242528 | 0.72 | ENPP2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | CHRNB2 3655/4885CHRNA4 4180/4885LMNA 3497/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | CHRNB2 3688/4885CHRNA4 4347/4885LMNA 3364/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | CHRNB2 3688/4885CHRNA4 4347/4885LMNA 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.